Search
Idecabtagene vicleucel
go.drugbank.com/drugs/DB16665ApprovedInvestigational[A232558,A232563,L32858] These therapies involve extracting and genetically manipulating T-cells from a patient to express a CAR for a tumor specific antigen. … [A232608] Idecabtagene vicleucel, also known as bb2121, is a chimeric antigen receptor (CAR) T-cell therapy like [axicabtagene ciloleucel] and [brexucabtagene autoleucel].
Pucotenlimab
go.drugbank.com/drugs/DB17552ApprovedInvestigationalIt received its first global approval in China in July 2022 for the treatment of solid tumours.[A257296] It is being investigated in other cancers.
Iptacopan
go.drugbank.com/drugs/DB16200ApprovedInvestigational[A262581] On December 6th, 2023, Iptacopan under the brand name Fabhalta was approved by the FDA for the treatment of adults with PNH. … Iptacopan is a small-molecule factor B inhibitor previously investigated as a potential treatment for the rare blood disease paroxysmal nocturnal hemoglobinuria (PNH) by inhibiting the complement factor
Tromethamine
go.drugbank.com/drugs/DB03754ApprovedInvestigationalIt is used in the synthesis of surface-active agents and pharmaceuticals; as an emulsifying agent for cosmetic creams and lotions, mineral oil and paraffin wax emulsions, as a biological buffer, and used
Vandetanib
go.drugbank.com/drugs/DB05294ApprovedInvestigationalVandetanib is an oral once-daily kinase inhibitor of tumour angiogenesis and tumour cell proliferation with the potential for use in a broad range of tumour types.
Zilganersen
go.drugbank.com/drugs/DB18161ApprovedInvestigational[L64096] The FDA approved zilganersen on September 3, 2026 for the treatment of Alexander disease in pediatric and adult patients, making it the first and only disease-modifying treatment for the condition
Talbutal
go.drugbank.com/drugs/DB00306ApprovedIllicitTalbutal, also called 5-allyl-5-sec-butylbarbituric acid, is a barbiturate with a short to intermediate duration of action. Talbutal is a schedule III drug in the U.S.
Baclofen
go.drugbank.com/drugs/DB00181ApprovedInvestigational[A245338] Baclofen was reintroduced in 1971 as a treatment for spasticity and was later approved by the FDA in 1977. … [L39429] Baclofen was investigated for use in alcohol dependence and withdrawal; however, evidence is limited and there is inconsistent evidence to suggest its clinical efficacy in managing alcohol
Categories: GABA-B Receptor AgonistsCeftizoxime
go.drugbank.com/drugs/DB01332ApprovedWithdrawnA semisynthetic cephalosporin antibiotic which can be administered intravenously or by suppository. The drug is highly resistant to a broad spectrum of beta-lactamases and is active against a wide range of both aerobic and anaerobic gram...
Categories: Antibacterials for Systemic Use, Antiinfectives for Systemic UsePramlintide
go.drugbank.com/drugs/DB01278ApprovedInvestigationalPramlintide is a relatively new adjunct treatment for diabetes (both type 1 and 2), developed by Amylin Pharmaceuticals.